Fosun Pharma: Controlled subsidiary's application for supplementary approval for a new indication has been approved.

Fosun Pharmaceutical announced that the supplementary application for a new indication for Hanlikang independently developed by its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary has been approved by the National Medical Products Administration.